Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 22;44(1):12.
doi: 10.1007/s10875-023-01616-2.

Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic

Giulia Anna Maria Luigia Costanzo #  1 , Carla Maria Deiana #  1 , Giuseppina Sanna  2 , Andrea Perra  3 , Marcello Campagna  1 , Andrea Giovanni Ledda  1 , Ferdinando Coghe  4 , Vanessa Palmas  2 , Riccardo Cappai  4 , Aldo Manzin  2 , Luchino Chessa  1 , Stefano Del Giacco  1 , Davide Firinu  5   6   7
Affiliations

Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic

Giulia Anna Maria Luigia Costanzo et al. J Clin Immunol. .

Abstract

Purpose: The purpose of this study is to investigate the kinetics of response against SARS-CoV-2 elicited by vaccination and/or breakthrough infection (occurred after 3 doses of BNT162b2) in a cohort CVID patients.

Methods: We measured humoral and cellular immunity using quantitative anti-spike antibody (anti-S-IgG) and neutralization assay and specific interferon-gamma release assay (IGRA) before and after the third or fourth dose of BNT162b2 and/or after COVID-19.

Results: In CVID, 58.3% seroconverted after 2 doses that increased to 77.8% after 3 doses. Between the second and third dose, there was a decline in humoral compartment that led to titers below the cutoff of 1:10 (MNA90%) in CVID. This was paralleled by a significantly lower proportion (30%) and reduced magnitude of the residual cellular response among CVID. The third dose achieved a lower titer of anti-S and nAb against the Wuhan strain than HC and significantly decreased the rate of those showing solely a positive neutralizing activity and those with simultaneous negativity of IGRA and nAbs; the differences in IGRA were overall reduced with respect to HC. At further sampling after breakthrough SARS-COV-2 infection, mostly in the omicron era, or fourth dose, 6 months after the last event, the residual nAb titer to Wuhan strain was still significantly higher in HC, while there was no significant difference of nAbs to BA.1. The rate of IGRA responders was 65.5% in CVID and 90.5% in HC (p=0.04), while the magnitude of response was similar. None of CVID had double negativity to nAbs and IGRA at the last sampling.

Conclusion: This data shows an increase of adaptive immunity in CVID after mRNA vaccination in parallel to boosters, accrual number of exposures and formation of hybrid immunity.

Keywords: BNT162b2; COVID-19; CVID; Covi-FERON; hybrid immunity; interferon-gamma release assay; vaccination.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–9. https://doi.org/10.1038/s41586-020-2814-7 . - DOI - PubMed
    1. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. https://doi.org/10.1126/science.abm0829 . - DOI - PubMed - PMC
    1. Katzenstein TL, Rasmussen LD, Drabe CH, Larsen CS, Hansen A-BE, Stærkind M, et al. Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: a Danish nationwide cohort study. Front Immunol. 2022;13:994253. https://doi.org/10.3389/fimmu.2022.994253 . - DOI - PubMed - PMC
    1. Shields AM, Burns SO, Savic S, Richter AG. Consortium UPC-. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147(3):870–5 e1. https://doi.org/10.1016/j.jaci.2020.12.620 . - DOI - PubMed
    1. Paris R. SARS-CoV-2 infection and response to COVID-19 vaccination in patients with primary immunodeficiencies. J Infect Dis. 2023;228(Supplement_1):S24–33. https://doi.org/10.1093/infdis/jiad145 . - DOI - PubMed - PMC

Publication types

LinkOut - more resources